The FDA has rejected Gilead’s filing for approval of filgotinib in rheumatoid arthritis. With the FDA asking to see data from an ongoing clinical trial, Gilead is unlikely to be able to refile until toward the middle of next year, pushing it still further behind its rivals for the JAK inhibitor market.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,